Effect of Aspirin on Pre-eclampsia and Fetal Growth Restriction in Obese Pregnant Women: A Randomized Controlled Clinical Trial

Aims: Obesity in pregnant women is a serious health problem that has many complications such as pre-eclampsia and fetal growth restriction (FGR). The aim of the present study was to evaluate the effect of aspirin on prevalence of pre-eclampsia and FGR in obese pregnant women. Materials Methods: This randomized controlled clinical trial was conducted on 187 pregnant women referring to birth center of Mofatteh Clinic, Yasuj University of Medical Sciences, Yasuj, Iran in 2017-2018. The subjects were selected using purposive sampling method and randomly divided into two groups; intervention group (n=89) and control group (n=98). The intervention group received 80mg/day aspirin and the control group received placebo at 13-20 weeks of gestation until 34 weeks of pregnancy. Data were analyzed by SPSS 21 software using Chi square test. Findings: The prevalence of pre-eclampsia (1.1 vs. 11.2) and FGR (3.4 vs. 21.4) were significantly lower in the intervention group compared to the control group (p 0.05). Conclusion: Administration of 80mg/daily of aspirin from 13-20 weeks of gestation in obese pregnant women reduces the incidence of pre-eclampsia and FGR, which could support the positive role of aspirin in preventing pre-eclampsia and FGR.